1. Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients
   Cuc Thi Thu Nguyen et al, 2024, Pharmacogenomics CrossRef
2. Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992–2009
   Yefei Zhang et al, 2014, Medical Oncology CrossRef
3. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression
   R. Obermannová et al, 2016, Annals of Oncology CrossRef
4. An update on the management of metastatic colorectal cancer in the elderly
   Gerardo Rosati et al, 2014, Colorectal Cancer CrossRef
5. Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients
   Pashtoon Murtaza Kasi et al, 2018, Drugs CrossRef
6. Safety and Efficacy of Radioembolization in Elderly (≥ 70 Years) and Younger Patients With Unresectable Liver-Dominant Colorectal Cancer
   Andrew S. Kennedy et al, 2016, Clinical Colorectal Cancer CrossRef
7. Aflibercept Plus Folfiri in Asian Patients with Pretreated Metastatic Colorectal Cancer: A Randomized Phase III Study
   Jin Li et al, 2018, Future Oncology CrossRef
8. Efficacy and Safety of Liver Chemoembolization Procedures, Combined with FOLFIRI Chemotherapy, in First-Line Treatment of Metastatic Colorectal Cancer in Patients with Oncogene Mutations
   Marcin Szemitko et al, 2023, Cancers CrossRef
9. First-Line Mono-Chemotherapy in Frail Elderly Patients with Metastatic Colorectal Cancer
   Umut Varol et al, 2014, Asian Pacific Journal of Cancer Prevention CrossRef